Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant dostarlimab in MMR-deficient/MSI-high stage II-III endometrial cancer
2024-512021-81-00Phase 2Authorised
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
- Start
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dostarlimab in endometrial adenocarcinoma, sponsored by Grupo Español de Investigación en Cáncer de Ovario. Primary endpoint: cCR. Planned start Dec 2025; status: authorised.
02
Drugs
dostarlimab
03
Conditions
endometrial adenocarcinoma
Beyond the preview
Go deeper on 2024-512021-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512021-81-00.